Filtros de búsqueda

Lista de obras de Mikkel Christensen

Adverse effects associated with high-dose olanzapine therapy in patients admitted to inpatient psychiatric care

artículo científico

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus

artículo científico publicado en 2013

Comment on: Gögebakan et al. Glucose-dependent insulinotropic polypeptide reduces fat-specific expression and activity of 11β-hydroxysteroid dehydrogenase type 1 and inhibits release of free fatty acids. Diabetes 2012;61:292-300.

artículo científico publicado en 2012

Diabetes: Add-on to metformin in T2DM--linagliptin or glimepiride?

artículo científico publicado en 2012

Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease

artículo científico publicado en 2014

Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists

scientific article published on 03 November 2019

GIP and the gut-bone axis - Physiological, pathophysiological and potential therapeutic implications

scientific article published on 09 November 2019

GIP's involvement in the pathophysiology of type 2 diabetes

scientific article published on 01 November 2019

GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.

artículo científico

Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes

artículo científico publicado en 2010

Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes

scientific article published on 16 July 2020

Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease

artículo científico publicado en 2019

Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans

artículo científico publicado en 2011

Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes

artículo científico publicado en 2013

High-Dose Glucagon Has Hemodynamic Effects Regardless of Cardiac Beta-Adrenoceptor Blockade: A Randomized Clinical Trial

artículo científico publicado en 2020

Lixisenatide for the treatment of type 2 diabetes.

artículo científico

Lixisenatide for type 2 diabetes mellitus

scientific article published on 11 March 2011

Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?

scientific article published on April 2010

Outcomes following calcium channel blocker exposures reported to a poison information center

Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies.

artículo científico

Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies

artículo científico publicado en 2013

Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men without Diabetes

artículo científico publicado en 2019

Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans

artículo científico publicado en 2014

The alpha-cell as target for type 2 diabetes therapy.

artículo científico publicado en 2011

The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.

artículo científico

The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials

artículo científico publicado en 2014

The unobtainable placebo: control of independent clinical research by industry?

artículo científico publicado en 2012

Therapy for obesity based on gastrointestinal hormones

artículo científico publicado en 2011

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda